title: SSAO substrates exhibiting insulin-like effects in adipocytes as a promising treatment option for metabolic disorders.
abstract: BACKGROUND
  Benzylamine exerts insulin-like effects in adipocytes (e.g., glucose uptake and antilipolysis) and improves glucose handling in rodents.
  
  
  RESULTS
  In murine adipocytes, benzylamine mimics another insulin action: it enhances apelin expression in a manner that is blocked by the semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1) inhibitor semicarbazide. It is shown that in human adipocytes, benzylamine activates glucose transport, but its effects are not additive to maximal insulin stimulation. Benzylamine effects are hydrogen peroxide dependent. They can be reproduced by novel substrates, but not by benzaldehyde.
  
  
  CONCLUSIONS
  Owing to the parallelism between the in vitro insulin mimicry and the in vivo improvement of glucose handling elicited by benzylamine in rodents, the SSAO/VAP-1 substrates, with stronger effects on human adipocytes than benzylamine, show promising applications for the treatment of insulin resistance.
authors.affiliation: Institut National de la Santé et de la Recherche Médicale, INSERM U858 équipe 3, Université Paul Sabatier, IFR150, Centre Hospitalier Universitaire de Rangueil, France.
authors.forename: Josep
authors.initials: J
authors.lastname: Mercader
authors.forename: Zsuzsa
authors.initials: Z
authors.lastname: Iffiú-Soltesz
authors.forename: Xavier
authors.initials: X
authors.lastname: Brenachot
authors.forename: Agota
authors.initials: A
authors.lastname: Földi
authors.forename: Petra
authors.initials: P
authors.lastname: Dunkel
authors.forename: Balázs
authors.initials: B
authors.lastname: Balogh
authors.forename: Camille
authors.initials: C
authors.lastname: Attané
authors.forename: Philippe
authors.initials: P
authors.lastname: Valet
authors.forename: Péter
authors.initials: P
authors.lastname: Mátyus
authors.forename: Christian
authors.initials: C
authors.lastname: Carpéné
mesh_terms: D016475:3T3 Cells; D017667:Adipocytes / Q000187:drug effects / Q000378:metabolism*; D054392:Adipokines; D006631:Amine Oxidase (Copper-Containing) / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000818:Animals; D000073861:Apelin; D001596:Benzylamines / Q000494:pharmacology*; D005786:Gene Expression Regulation / Q000187:drug effects; D005947:Glucose / Q000378:metabolism; D006801:Humans; D006861:Hydrogen Peroxide / Q000378:metabolism; D007328:Insulin / Q000378:metabolism*; D007333:Insulin Resistance; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics; D008659:Metabolic Diseases / Q000188:drug therapy*; D051379:Mice; D012663:Semicarbazides / Q000494:pharmacology
chemical_list: D054392:Adipokines; D000073861:Apelin; C402826:Apln protein, mouse; D001596:Benzylamines; D007328:Insulin; D036341:Intercellular Signaling Peptides and Proteins; D012663:Semicarbazides; C010059:carbamylhydrazine; C030796:benzylamine; D006861:Hydrogen Peroxide; D006631:Amine Oxidase (Copper-Containing); D005947:Glucose